全文获取类型
收费全文 | 10350篇 |
免费 | 753篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 364篇 |
妇产科学 | 248篇 |
基础医学 | 1592篇 |
口腔科学 | 156篇 |
临床医学 | 1141篇 |
内科学 | 2088篇 |
皮肤病学 | 168篇 |
神经病学 | 1257篇 |
特种医学 | 151篇 |
外科学 | 902篇 |
综合类 | 115篇 |
一般理论 | 18篇 |
预防医学 | 1191篇 |
眼科学 | 218篇 |
药学 | 579篇 |
中国医学 | 23篇 |
肿瘤学 | 838篇 |
出版年
2023年 | 57篇 |
2022年 | 87篇 |
2021年 | 284篇 |
2020年 | 159篇 |
2019年 | 284篇 |
2018年 | 269篇 |
2017年 | 213篇 |
2016年 | 235篇 |
2015年 | 254篇 |
2014年 | 353篇 |
2013年 | 541篇 |
2012年 | 749篇 |
2011年 | 774篇 |
2010年 | 412篇 |
2009年 | 356篇 |
2008年 | 586篇 |
2007年 | 695篇 |
2006年 | 624篇 |
2005年 | 638篇 |
2004年 | 596篇 |
2003年 | 573篇 |
2002年 | 492篇 |
2001年 | 191篇 |
2000年 | 105篇 |
1999年 | 105篇 |
1998年 | 126篇 |
1997年 | 119篇 |
1996年 | 116篇 |
1995年 | 73篇 |
1994年 | 71篇 |
1993年 | 82篇 |
1992年 | 69篇 |
1991年 | 62篇 |
1990年 | 48篇 |
1989年 | 56篇 |
1988年 | 56篇 |
1987年 | 49篇 |
1986年 | 46篇 |
1985年 | 41篇 |
1984年 | 49篇 |
1983年 | 26篇 |
1982年 | 51篇 |
1981年 | 59篇 |
1980年 | 30篇 |
1979年 | 28篇 |
1978年 | 30篇 |
1977年 | 24篇 |
1976年 | 18篇 |
1971年 | 14篇 |
1970年 | 16篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
2.
Caroline E. Sloan Judy Zhong Dinushika Mohottige Rasheeda Hall Clarissa J. Diamantidis Leight E. Boulware Virginia Wang 《Seminars in dialysis》2020,33(6):440-448
Caring for patients with end-stage kidney disease (ESKD) in the United States is challenging, due in part to the complex epidemiology of the disease's progression as well as the ways in which care is delivered. As CKD progresses toward ESKD, the number of comorbidities increases and care involves multiple healthcare providers from multiple subspecialties. This occurs in the context of a fragmented US healthcare delivery system that is traditionally siloed by provider specialty, organization, as well as systems of payment and administration. This article describes the role of care fragmentation in the delivery of optimal ESKD care and identifies research gaps in the evidence across the continuum of care. We then consider the impact of care fragmentation on ESKD care from the patient and health system perspectives and explore opportunities for system-level interventions aimed at improving care for patients with ESKD. 相似文献
3.
4.
5.
6.
7.
Bernard P Halloran Virginia L Ferguson Steven J Simske Andrew Burghardt Laura L Venton Sharmila Majumdar 《Journal of bone and mineral research》2002,17(6):1044-1050
To determine whether the mouse loses bone with aging and whether the changes mimic those observed in human aging, we examined the changes in the tibial metaphysis and diaphysis in the male C57BL/6J mouse over its life span using microcomputed tomography (microCT). Cancellous bone volume fraction (BV/TV) decreased 60% between 6 weeks and 24 months of age. Loss was characterized by decreased trabecular number (Tb.N), increased trabecular spacing (Tb.Sp), and decreased connectivity. Anisotropy decreased while the structure model index increased with age. Cortical bone thickness increased between 6 weeks and 6 months of age and then decreased continuously to 24 months (-12%). Cortical bone area (Ct.Ar) remained constant between 6 and 24 months. Fat-free weight reached a peak at 12 months and gradually declined to 24 months. Total mass lost between 12 and 24 months reached 10%. Overall, the age-related changes in skeletal mass and architecture in the mouse were remarkably similar to those seen in human aging. Furthermore, the rapid early loss of cancellous bone suggests that bone loss is not just associated with old age in the mouse but rather occurs as a continuum from early growth. We conclude that the C57BL/6J male mouse maybe a useful model to study at least some aspects of age-related bone loss in humans. 相似文献
8.
9.
PURPOSE: To evaluate a computational approach that incorporates experimental data in preclinical models to depict doxorubicin human tissue pharmacokinetics. EXPERIMENTAL DESIGN: Beagle dogs were given 2 mg/kg doxorubicin as i.v. bolus, 4-h infusion, or 96-h infusion. Concentrations in plasma, prostate (target tissue), heart (toxicity), and major tissues for disposition were determined and modeled. Model parameters were obtained after the bolus injection with model validation based on the 4-h and 96-h infusion data. Clinical pharmacokinetic data and scale-up gave doxorubicin profiles in human prostate and heart. RESULTS: In agreement with in vitro results, tissues were best modeled with two compartments, one rapidly and one slowly equilibrating. The developed tissue distribution model predicted concentrations for all three administration regimens well, with an average deviation of 34% (median, 29%). Interspecies scale-up to humans showed that the change from a bolus injection to a slow, 96-h infusion (a) had different effects on the drug partition and accumulation in heart and prostate, and (b) lowered the peak concentration in the plasma by approximately 100-fold but had relatively little effect on maximal heart concentration ( approximately 33% lower). The simulated drug exposure in a human prostate was above the exposure required to inhibit tumor proliferation but was 30 to 50 times below that needed for cell death. CONCLUSION: The present study shows a computation-based paradigm for translating in vitro and in vivo preclinical data and to estimate and compare the drug delivery and pharmacokinetics in target tissues after different treatment schedules. 相似文献
10.
M Guillaume Wientjes Jenny H Zheng Leijun Hu Yuebo Gan Jessie L-S Au 《Clinical cancer research》2005,11(11):4204-4211
PURPOSE: The present study evaluated the tissue distribution and targeting advantage of intraprostatic chemotherapy. EXPERIMENTAL DESIGN: We studied the delivery and spatial distribution of a fluorescent drug, doxorubicin, in the prostate of beagle dogs, after intraprostatic or i.v. administration. Drug concentrations were measured using high-performance liquid chromatography and confocal fluorescence microscopy. RESULTS: I.v. and intraprostatic injections yielded qualitatively and quantitatively different doxorubicin distribution in the prostate. A relatively homogeneous distribution was found after i.v. administration, whereas intraprostatic injection yielded a highly heterogeneous distribution with >10-fold higher concentrations localized in a cone-shaped glandular lobule bound by fibromuscular stroma, compared with other parts of the prostate. Compared with i.v. injection, intraprostatic injection yielded, on average, approximately 100-fold higher tissue-to-plasma concentration ratio, ranging from 963-fold near the injection site to 19-fold in the contralateral half of the prostate. The drug distribution within the prostate further suggests an important role for acinar flow in intraprostatic drug transport. CONCLUSIONS: Intraprostatic administration represents a viable option to deliver high drug concentrations within the prostate. The results further suggest the fibromuscular stroma separating the prostatic lobules as a major barrier to drug transport and convective flow as an important drug transport mechanism in the prostate. 相似文献